Democrats are on the brink of passing a historic set of drug price reforms. How will they impact patients, insurers and the drug industry?
Leslie Walker
Leslie is a senior reporter and producer for Tradeoffs covering a wide range of health policy issues including prescription drugs and Medicare. Her story, “Inside Big Health Insurers’ Side Hustle,” was awarded first place in audio reporting by the Association of Health Care Journalists and her work has been featured on Marketplace, NPR and STAT News. Before Tradeoffs, Leslie worked as a freelance writer and editor, in nonprofit communications, and at a health care social enterprise. She lives in San Francisco.
Posted inInsurance
The Costly, Confusing Medicare Choices Facing 62 Million Americans
It’s Medicare open enrollment time, but shopping for a new plan is much harder and riskier than it seems.
Posted inHealth Law
Can Democrats Reconcile Their Health Policy Differences?
Democratic lawmakers face tough health care compromises as they struggle to secure votes for their blockbuster spending bill.
Posted inInsurance
Inside Big Health Insurers’ Side Hustle
America’s largest health insurance companies moonlight as obscure middlemen, managing billions in health care spending for many of the country’s biggest employers.
Posted inHealth Law
The Next Big Challenge to Abortion Rights
A new Texas law and an upcoming Supreme Court case could drastically alter abortion access in America.
Posted inHealth Equity
Sacrifices and Small Wins: The Fight Against Rising Gun Violence
As gun violence continues to soar in U.S. cities, one violence prevention specialist tries to stem the tide of homicides in his hometown.
Posted inHealth Equity
One Woman’s Year Surviving the Pandemic with a Disability
A young woman living with cerebral palsy shares the struggles, fears and silver linings she’s experienced during the pandemic.
Posted inCost of Care
The Aducanumab Aftermath: The Industry
How is the pharmaceutical industry reacting to the FDA’s surprising approval of a controversial Alzheimer’s drug?
Posted inCost of Care
The Aducanumab Aftermath: The Payer
A costly new Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.
Posted inMental Health
The Aducanumab Aftermath: The Patient
One patient shares her hopes and concerns about a costly new Alzheimer’s drug.